These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10655447)

  • 21. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary.
    Fisher B
    J Clin Oncol; 1999 May; 17(5):1632-9. PubMed ID: 10334553
    [No Abstract]   [Full Text] [Related]  

  • 26. Specific keynote: chemoprevention of ovarian cancer: the journey begins.
    Ozols RF; Daly MB; Klein-Szanto A; Hamilton TC; Bast RC; Brewer MA
    Gynecol Oncol; 2003 Jan; 88(1 Pt 2):S59-66; discussion S67-70. PubMed ID: 12586088
    [No Abstract]   [Full Text] [Related]  

  • 27. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia.
    De Palo G; Veronesi U; Marubini E; Camerini T; Chiesa F; Nava M; Formelli F; Del Vecchio M; Costa A; Boracchi P
    J Cell Biochem Suppl; 1995; 22():11-7. PubMed ID: 8538187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Breakthrough in breast cancer chemoprevention].
    Kahán Z; Thurzó L
    Orv Hetil; 2003 Mar; 144(13):597-603. PubMed ID: 12728784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Chemoprevention of breast cancer by tamoxifen: should we still ask this question?].
    Sasco AJ
    Rev Epidemiol Sante Publique; 1999 Jun; 47(3):279-85. PubMed ID: 10422121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic retinoid fenretinide in breast cancer chemoprevention.
    Bonanni B; Lazzeroni M; Veronesi U
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Results of the NSABP clinical trial for the prevention of cancer of the breast].
    Namer M
    Bull Cancer; 1998 Apr; 85(4):299. PubMed ID: 9752291
    [No Abstract]   [Full Text] [Related]  

  • 32. Tamoxifen for the prevention of breast cancer in high-risk women.
    Sweeney FW; Newton WP
    J Fam Pract; 1999 Feb; 48(2):90-1. PubMed ID: 10037532
    [No Abstract]   [Full Text] [Related]  

  • 33. Preventive therapy for breast cancer: a consensus statement.
    Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
    Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemoprevention of breast cancer.
    Costa A; Sacchini V; Bonanni B; D'Aiuto G
    Eur J Cancer Prev; 1994 Jul; 3(4):361-4. PubMed ID: 7950891
    [No Abstract]   [Full Text] [Related]  

  • 35. Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?
    Bergh J
    Lancet; 2003 Jul; 362(9379):183-4. PubMed ID: 12885476
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prevention of breast cancer using tamoxifen].
    Foidart JM; Colin C; Lifrange E
    Rev Med Liege; 1998 Apr; 53(4):225-6. PubMed ID: 9641022
    [No Abstract]   [Full Text] [Related]  

  • 37. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tamoxifen in prophylaxis of breast cancer].
    Bogush TA; Bogush EA
    Antibiot Khimioter; 2001; 46(1):30-4. PubMed ID: 11221083
    [No Abstract]   [Full Text] [Related]  

  • 39. USPSTF releases guidelines on breast-cancer chemoprevention.
    Bradbury J
    Lancet; 2002 Jul; 360(9326):63. PubMed ID: 12114050
    [No Abstract]   [Full Text] [Related]  

  • 40. Chemoprevention of breast cancer with fenretinide.
    Torrisi R; Decensi A; Formelli F; Camerini T; De Palo G
    Drugs; 2001; 61(7):909-18. PubMed ID: 11434448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.